Preclinical studies emphasizing the inhibition of PD-1/PD-L1 in solid tumors underscore the potential to alleviate T-cell suppression within TME, thereby promoting the anti-tumor efficacy of BSABs [281]. Here, CD274 is linked to neoplasm.